Navigation Links
Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
Date:7/22/2009

dults over age 65 years similar to the severe illness witnessed in children. It is estimated that RSV infects more than 8.5 million adults annually, including the elderly over age 65 years. This virus is responsible for approximately 900,000 hospitalizations annually in the United States and major European countries. In the United States alone, RSV leads to 177,500 hospitalizations in high risk adults resulting in annual medicals costs exceeding $1 billion.

ABOUT NOVAVAX

Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biotechnology company creating novel vaccines, including H1N1, to address a broad range of infectious diseases worldwide using advanced proprietary virus-like-particle (VLP) technology. The company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the company's various filings with the Securities and Exchange Commission.

Forward Looking Statement

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future results; further testing is required before an IND may be filed with the FDA and human clin
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
2. Novavax Announces Repayment of $5 Million of Convertible Debt
3. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
4. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
5. Novavax Appoints Stanley Erck to Board of Directors
6. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
7. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
8. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
9. Novavax Reports First Quarter 2009 Financial Results
10. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
11. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Gallus BioPharmaceuticals , LLC, ... manufacturing organization (CMO) announced today that it has ... company focused on the development of innovative approaches ... anti-prostate specific membrane antigen (PSMA) monoclonal antibody used ... the agreement the antibody will be produced in ...
(Date:8/20/2014)... An analysis of patented university inventions licensed to ... path to commercialization. To open these roadblocks, the ... results during the discovery stage could lead to ... are frequently derived from discoveries made in university ... well known during clinical trials, which have a ...
(Date:8/20/2014)... High performance computing (HPC) will ... complete climate and Earth system model to address ... , Eight national laboratories, including Lawrence Livermore ... for Atmospheric Research, four academic institutions and one ... national laboratories include Argonne, Brookhaven, Lawrence Berkeley, Los ...
(Date:8/20/2014)... Not long ago, it was more or less ... in the development cycle – even after the final ... that, like many things GxP, expectations for early E&L ... drug sponsors have been required by authorities to provide ... I/II. It’s not only clinical trial material containers causing ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... Report Represents Major Step in Cancer Genome Research, ... a Beckman Coulter company, announced today that its,Genomic ... released study from,Johns Hopkins Kimmel Cancer Center. The ... the discovery of 200 genes linked to breast ...
... Biosciences Inc. announces the,launch of its SurgiMend(TM) Collagen ... 510(k) clearance from the U.S. Food and Drug,Administration ... and,reconstructive surgery, including breast reconstruction, and for tendon,augmentation, ... and,muscle flap reinforcement indications. "SurgiMend has been ...
... to empower transplant patients ... and ... US,Inc. (Pink Sheets: ALPMF), a leader in the field of ... organization, announced a collaborative partnership to jointly,develop further materials for ...
Cached Biology Technology:Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers 2Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers 3TEI Biosciences Launches SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 3
(Date:8/20/2014)... finds life can persist in a cold, dark world. ... team that examined waters and sediments from a shallow ... the extreme environment supports microbial ecosystems. , The ... colleagues has implications for life in other extreme environments, ... findings are published in the current edition of the ...
(Date:8/20/2014)... MA Using population-based screening outcomes of approximately 3 ... including four researchers at the University of Massachusetts Medical ... immunodeficiency (SCID) can be successfully implemented across public health ... published in the Aug. 20 issue of the ... ) showed the rate of SCID in newborns is ...
(Date:8/20/2014)... are athletes who have suffered concussions ready to return ... found that high school athletes who head back on ... a significant regression in their abilities to simultaneously walk ... seen in changes in their balance and/or altered walking ... of the 12 had returned to activity in less ...
Breaking Biology News(10 mins):University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... for Biodiversity Science (QCBS) cordially invites you to its ... from government, the private sector and NGOs to reflect ... the International Year of Biodiversity. CONFIRMED SPEAKERS TO ... the H. John Heinz III Centre for Science, Economics, ...
... tonnes of carbon dioxide a year from the time food ... more than 20% of total yearly emissions. That is what ... the first time that human excrements contribute to water pollution, ... from the Universidad de Almera (UAL) has estimated the environmental ...
... the University of Illinois at Chicago have been awarded more ... Institute to investigate both the acquired and familial causes of ... diagnosis and targets for cures. The five years of ... John Solaro, distinguished university professor and head of physiology and ...
Cached Biology News:Every person emits 2 tons of CO2 a year through eating 2$12 million grant to probe root causes of heart failure 2
... Not treated (or medium binding) ... and binds biomolecules through passive interactions,• ... of large molecules, such as antibodies, ... can interact with the surface,• Binding ...
... optically clear polystyrene formulation , High antibody-binding ... , Plates are certified for performance ... , Eight-well strips fit snugly in ... in use even if turned upside down ...
... for in vitro diagnostic assays, all EIA/RIA ... for uniform binding, high optical clarity and ... are part of the Certified Surface Chemistry ... be within QA release specifications. Linkage: This ...
... adsorption and clarification reagent; Ideal for ... of antibodies, proteins, nucleic acids, & ... cross-reactivity, and improves downstream processing; Utilizes ... non-ionic adsorbent supplied as a suspension ...
Biology Products: